Metabolite Profiling of LADA Challenges the View of a Metabolically Distinct Subtype

Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)–positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis. However, it is not always easy to distinguish LADA from type 1 or type 2 diabetes. In this study, we examined whether metabolite profiling could help to distinguish LADA (n = 50) from type 1 diabetes (n = 50) and type 2 diabetes (n = 50). Of 123 identified metabolites, 99 differed between the diabetes types. However, no unique metabolite profile could be identified for any of the types. Instead, the metabolome varied along a C-peptide–driven continuum from type 1 diabetes via LADA to type 2 diabetes. LADA was more similar to type 2 diabetes than to type 1 diabetes. In a principal component analysis, LADA patients overlapping with type 1 diabetes progressed faster to insulin therapy than those overlapping with type 2 diabetes. In conclusion, we could not find any unique metabolite profile distinguishing LADA from type 1 and type 2 diabetes. Rather, LADA was metabolically an intermediate of type 1 and type 2 diabetes, with those patients closer to the former showing a faster progression to insulin therapy than those closer to the latter.

[1]  L. Groop,et al.  Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. , 1999, Diabetes.

[2]  S. Wold,et al.  Orthogonal projections to latent structures (O‐PLS) , 2002 .

[3]  U. Edlund,et al.  Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. , 2008, Analytical chemistry.

[4]  Henrik Antti,et al.  Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. , 2016, Molecular bioSystems.

[5]  L. Groop,et al.  Genetic Similarities Between Latent Autoimmune Diabetes in Adults, Type 1 Diabetes, and Type 2 Diabetes , 2008, Diabetes.

[6]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[7]  S. Vollset,et al.  Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: the Hordaland Homocysteine Study. , 1999, The American journal of clinical nutrition.

[8]  L. Groop,et al.  Metabolite Profiling Reveals Normal Metabolic Control in Carriers of Mutations in the Glucokinase Gene (MODY2) , 2013, Diabetes.

[9]  Tiinamaija Tuomi,et al.  The many faces of diabetes: a disease with increasing heterogeneity , 2014, The Lancet.

[10]  L. Groop,et al.  Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of Disease , 1993, Diabetes.

[11]  W. Kraus,et al.  Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. , 2012, American heart journal.

[12]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[13]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[14]  I. Fox,et al.  Metabolic basis for disorders of purine nucleotide degradation. , 1981, Metabolism: clinical and experimental.

[15]  Thomas Moritz,et al.  Metabolomic analysis of a human oral glucose tolerance test reveals fatty acids as reliable indicators of regulated metabolism , 2010, Metabolomics.

[16]  P. Spégel,et al.  Development of a gas chromatography/mass spectrometry based metabolomics protocol by means of statistical experimental design , 2011, Metabolomics.

[17]  F. Toledo,et al.  Increased Levels of Plasma Acylcarnitines in Obesity and Type 2 Diabetes and Identification of a Marker of Glucolipotoxicity , 2010, Obesity.

[18]  L. Groop,et al.  Metabolite Pro fi ling Reveals Normal Metabolic Control in Carriers of Mutations in the Glucokinase Gene ( MODY 2 ) , 2012 .

[19]  A. de Leiva,et al.  Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7. Diabetes Care 2013;36:908–913 , 2014, Diabetes Care.

[20]  R. Holman,et al.  UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes , 1997, The Lancet.

[21]  A. de Leiva,et al.  Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype , 2013, Diabetes Care.

[22]  Johan Lindberg,et al.  Predictive metabolite profiling applying hierarchical multivariate curve resolution to GC-MS data--a potential tool for multi-parametric diagnosis. , 2006, Journal of proteome research.

[23]  Henrik Antti,et al.  Predictive metabolomics evaluation of nutrition-modulated metabolic stress responses in human blood serum during the early recovery phase of strenuous physical exercise. , 2009, Journal of proteome research.

[24]  Y. Ozkan,et al.  Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. , 2002, International journal of cardiology.

[25]  L. Groop,et al.  Islet Cell Antibodies Identify Latent Type I Diabetes in Patients Aged 35–75 Years at Diagnosis , 1986, Diabetes.